首页> 美国卫生研究院文献>Rheumatology Advances in Practice >Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. Reply
【2h】

Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. Reply

机译:评论:评价大血管巨型细胞动脉凋亡的辅助霉蛋白。回复

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dear Editor, We thank Drs Mazumder and Mukhtyar for their positive commentary [1] on our paper [2]. It is increasingly recognized that GCA is a heterogeneous disease on the basis not only of clinical phenotypes, but also of immunopathological characteristics. Similar to your thoughts, we propose that future research efforts focus on all these aspects of the disease to map the distinct endotypes and, ultimately, carve the path towards precision medicine in GCA. Although there is emerging evidence to support the distinct subsets within the spectrum of GCA, these observations require validation in multicentre studies, and further research efforts are required to explore in depth the immunobiological drivers of these disease endotypes.
机译:亲爱的E.迪茨,我们感谢Mazumder和Mukhtyar的纸张积极评论[1] [2]。越来越认识到,GCA是基于临床表型的异质疾病,也是免疫病理特征。与您的思想类似,我们建议未来的研究努力关注疾病的所有这些方面,以映射不同的内型内容,最终雕刻GCA的精密药物。虽然存在新兴的证据来支持GCA的频谱内的不同子集,但这些观察结果需要在多环境研究中验证,并且需要进一步的研究努力来探索这些疾病内型的免疫生理驱动因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号